News
”The main priority in our commercial efforts right now is to grow the user base, and we are clearly seeing that our ability to generate new customers is better than ever. In fact, during the first two quarters of 2022, we have already had as many customers (66) as we had for the full year 2021. Volumes will increase with each customer as pandemic-related backlogs are worked through and when user experience from the Episealer®…
Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee technology and clinical results are being presented at the 5th International Conference on Meniscus Science and Surgery (Luxembourg, July 7-9, 2022). The presentation is held by Prof Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden. The presentation will focus on the expected clinical outcome after resurfacing of cartilage defects in the knee, and the latest results from an ongoing European…
Episurf Medical (Nasdaq: EPIS B) meddelar idag att knäteknologin Episealer® och kliniska resultat presenteras vid 5th International Conference on Meniscus Science and Surgery (Luxemburg, 7-9 juli 2022). Presentationen hålls av prof. Karl Eriksson från Södersjukhuset och Karolinska Institutet, Stockholm. Presentationen kommer att fokusera på förväntade kliniska resultat efter ytersättning av broskskador i knäet, och de senaste resultaten från en pågående europeisk multicenterstudie kommer att presenteras som en del av presentationen. ”Segmentet som vi fokuserar på,…
Episurf Medical AB (NASDAQ: EPIS B): Under juni har aktieägare nyttjat 115 057 teckningsoptioner (TO4B). Antal aktier har under denna teckningsperiod ökat med 115 057 B-aktier och antalet röster har ökat med 115 057. Antalet teckningsoptioner som kvarstår för framtida teckningsperioder är 1 299 084. Villkoren för teckningsoptionerna finns publicerade på Episurf Medicals hemsida. Det totala antalet aktier uppgår till 266 655 043, varav 479 357 A-aktier och 266 175 686 B-aktier. Det totala antalet…
Episurf Medical AB (NASDAQ: EPIS B): During June, shareholders exercised 115,057 warrants (TO4B). The number of shares has increased by 115,057 B-shares during the subscription period, and the number of votes has increased by 115,057. The number of warrants remaining for future subscription periods is 1,299,084. The terms of the warrants are published on Episurf Medical's website. The total number of shares amounts to 266,655,043, where 479,357 are A-shares, and 266,175,686 are B-shares. The total…
Episurf Medical (Nasdaq: EPIS B) meddelar idag att den första operationen i Indien med knäledsimplantatet Episealer® har planerats. Indien erbjuder en unik möjlighet att ta sig in på en betydande marknad med Episealer®-teknologin. Episurf Medical har ett nära samarbete med Prof. Niek van Dijk och Prof. doktor João Espregueira-Mendes som har hjälpt till med att introducera Episealer® till lokala ortopeder. Båda är rådgivare till Episurf Medical. ”Vi erbjuder nu Episealer®-teknologin till våra indiska kunder, och…
Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery in India with the knee implant Episealer® has been scheduled. India presents a unique opportunity to enter a vast market with the Episealer® technology. Episurf Medical has worked closely with Prof. Niek van Dijk and Prof. Doctor João Espregueira-Mendes who have aided in introducing local orthopaedic surgeons to the Episealer® technology. Both are advisors to Episurf Medical. “We are now offering the Episealer® technology…
Episurf Medical (Nasdaq: EPIS B) meddelar idag att den vetenskapliga sammanfattningen “Comparable clinical outcomes after autologous matrix-induced chondrogenesis versus implantation of single patient-specific metal implants in focal femoral chondral lesions of the middle-aged patient” har accepterats för podiumpresentation vid en tysk ortopedkongress (German Congress of Orthopaedics and Traumatology, DKOU 2022) i Berlin, Tyskland, den 25 – 28 oktober 2022. Presentationen kommer hållas av dr Clemens Kösters från Maria-Josef-Hospital i Greven, Tyskland. ”Vi har nu kommit…
Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Comparable clinical outcomes after autologous matrix-induced chondrogenesis versus implantation of single patient-specific metal implants in focal femoral chondral lesions of the middle-aged patient” has been accepted for a podium presentation at the German Congress of Orthopaedics and Traumatology, DKOU 2022, which will take place in Berlin, Germany, on October 25-28, 2022. The presentation will be held by Priv.-Doz. Dr. med. Clemens Kösters, Maria-Josef-Hospital Greven, Germany.…